Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants
- Conditions
- Respiratory Syncytial Virus
- Registration Number
- NCT04221412
- Lead Sponsor
- Janssen Sciences Ireland UC
- Brief Summary
The purpose of this pre-approval access program is to provide treatment to immunocompromised participants with serious/life-threatening diseases or conditions (Respiratory Syncytial Virus \[RSV\] infection) and to collect the safety data to understand the safety profile of JNJ-53718678.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does JNJ-53718678 utilize to combat RSV in immunocompromised patients?
How does JNJ-53718678 compare to standard-of-care treatments for severe RSV infections in terms of efficacy and safety?
Are there specific biomarkers that can predict which immunocompromised patients will respond best to JNJ-53718678 therapy?
What are the known or potential adverse events associated with JNJ-53718678 and how can they be managed in clinical practice?
What are the current developments in RSV antiviral therapies, and how does JNJ-53718678 fit into the broader therapeutic landscape compared to other investigational drugs like ALX-0171 or ETC-1002?